Condensed Interim Consolidated Financial Statements

For the Six Months Ended February 28, 2014

 

(In US Dollars)

 

(Unaudited – Prepared by Management)

 

 
 

 

NOTICE OF NO AUDITOR REVIEW OF

 

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

 

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company’s management.

 

The Company’s independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity’s auditor.

 

2
 

 

Stellar Biotechnologies, Inc.

Condensed Interim Consolidated Statements of Financial Position

(Unaudited - Prepared by Management)

(Expressed in US Dollars )

 

   February 28,   August 31, 
   2014   2013 
         
Assets:          
           
Current assets:          
Cash and cash equivalents  $15,840,974   $7,859,889 
Amounts receivable  (Note 4)   69,479    177,720 
Deferred financing costs   -    62,027 
Prepaid expenses   80,000    34,886 
Total current assets   15,990,453    8,134,522 
           
Noncurrent assets:          
Property, plant and equipment  (Note 5)   426,185    246,269 
Licensing rights (Note 6)   102,381    116,667 
Deposits   15,900    15,900 
Total noncurrent assets   544,466    378,836 
Total Assets  $16,534,919   $8,513,358 
           
Liabilities and Shareholders' Equity (Deficiency):          
           
Current liabilities:          
Accounts payable and accrued liabilities  $520,140   $454,063 
Warrant liability, current portion (Note 8)   1,242,443    3,454,745 
Total current liabilities   1,762,583    3,908,808 
           
Long-term liabilities:          
Warrant liability, less current portion (Note 8)   5,641,655    7,746,062 
Total Liabilities   7,404,238    11,654,870 
           
Shareholders' equity (deficiency):          
Share capital (Note 8)   36,018,971    13,180,677 
Shares subscribed (Note 8)   -    5,155,674 
Shares to be issued (Note 8)   1,070,909    1,493,637 
Share-based payment reserve (Note 8)   2,862,666    2,232,526 
Deficit   (30,821,865)   (25,204,026)
Total shareholders' equity (deficiency)   9,130,681    (3,141,512)
Total Liabilities and Shareholders' Equity (Deficiency)  $16,534,919   $8,513,358 

 

Nature of Operations and Going Concern (Note 1)

Commitments (Note 7)

Events After the Reporting Period (Note 14)

 

These condensed interim consolidated financial statements were approved for issuance by the Board of Directors on April 9, 2014 and are signed on its behalf by:

 

Director Signed: "Frank Oakes"  
     
Director Signed: "Mayank Sampat "  

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

3
 

 

Stellar Biotechnologies, Inc.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Unaudited - Prepared by Management)

(Expressed in US Dollars )

 

   Three Months Ended   Six Months Ended 
   February 28,   February 28,   February 28,   February 28, 
   2014   2013   2014   2013 
                 
Revenues:                    
Contract and collaboration income  $72,000   $15,000   $87,000   $30,000 
Commercial sales   19,103    9,375    26,688    39,225 
Grant revenue   -    37,106    36,579    107,983 
    91,103    61,481    150,267    177,208 
                     
Costs of Production, Aquaculture and Grants:                    
Costs of production and aquaculture   96,868    63,843    182,720    156,440 
Grant costs   -    37,106    35,848    107,983 
    96,868    100,949    218,568    264,423 
Gross Margin (Loss)   (5,765)   (39,468)   (68,301)   (87,215)
                     
Expenses:                    
Salaries, wages and benefits   312,945    171,520    742,444    356,162 
Research and development   536,621    236,832    908,452    506,460 
Legal, consulting and professional services   96,446    61,864    180,752    175,263 
Share-based payments (Note 8)   201,209    157,773    706,423    320,689 
General and administration   242,749    165,734    423,885    289,000 
Amortization and depreciation   48,106    30,951    79,057    61,902 
Allocation of expenses to grant costs   -    (15,539)   (14,517)   (43,651)
    1,438,076    809,135    3,026,496    1,665,825 
                     
Other Income:                    
Foreign exchange loss   (266,941)   (29,003)   (337,010)   (29,954)
Change in fair value of warrant liability (Note 8)   1,469,086    (2,767,283)   (2,200,472)   (2,628,621)
Interest income   15,943    1,762    26,640    2,633 
    1,218,088    (2,794,524)   (2,510,842)   (2,655,942)
                     
Loss Before Income Tax   (225,753)   (3,643,127)   (5,605,639)   (4,408,982)
Income tax expense    12,200    800    12,200    800 
Loss and Comprehensive Loss for the Period  $(237,953)  $(3,643,927)  $(5,617,839)  $(4,409,782)
                     
Loss per common share - basic and diluted  $(0.00)  $(0.07)  $(0.08)  $(0.09)
Weighted average number of common shares outstanding   75,036,352    50,679,214    73,491,305    48,827,422 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

4
 

 

Stellar Biotechnologies, Inc.

Condensed Interim Consolidated Statements of Cash Flows

(Unaudited - Prepared by Management)

(Expressed in US Dollars )

 

   Six Months Ended 
   February 28,   February 28, 
   2014   2013 
         
Cash Flows Used In Operating Activities:          
Loss for the period  $(5,617,839)  $(4,409,782)
           
Items not affecting cash:          
Amortization and depreciation   79,057    61,902 
Share-based payments   706,423    320,689 
Foreign exchange (gain) loss   24,989    29,102 
Change in fair value of warrant liability   2,200,472    2,628,621 
           
Changes in non-cash working capital items:          
Amounts receivable   108,241    (38,979)
Deferred financing costs   62,027    - 
Prepaid expenses   (45,114)   14,943 
Accounts payable and accrued liabilities   66,077    (134,013)
Deferred revenue   -    16,657 
Net cash used in operating activities   (2,415,667)   (1,510,860)
           
Cash Flows From Financing Activities:          
Proceeds from exercise of warrants and options   4,187,331    - 
Share subscription proceeds   7,000,000    1,509,998 
Share issuance costs   (520,903)   (74,817)
Net cash provided by financing activities   10,666,428    1,435,181 
           
Cash Flows Used In Investing Activities:          
Acquisition of property, plant and equipment   (244,687)   (2,411)
Net cash used in investing activities   (244,687)   (2,411)
Effect of exchange rate changes on cash and cash equivalents   (24,989)   852 
Net change in cash and cash equivalents   7,981,085    (77,238)
Cash and cash equivalents - beginning of period   7,859,889    998,998 
Cash and cash equivalents - end of period  $15,840,974   $921,760 
           
Cash (demand deposits)  $11,021,011   $432,791 
Cash equivalents   4,819,963    488,969 
Cash and cash equivalents  $15,840,974   $921,760 

 

Supplemental disclosure of non-cash transactions (Note 11)

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

5
 

 

Stellar Biotechnologies, Inc.

Condensed Interim Consolidated Statements of Changes in Equity

(Unaudited - Prepared by Management)

(Expressed in US Dollars )

 

                   Share-based         
   Number of   Share   Shares   Shares to   Payment         
   Shares   Capital   Subscribed   be Issued   Reserve   Deficit   Total 
                             
Balance - August 31, 2012   45,413,561   $8,016,895   $-   $1,493,637   $1,658,591   $(10,317,513)  $851,610 
                                    
Proceeds of private placements   5,998,400    1,509,998    -    -    -    -    1,509,998 
Issuance costs of private placements   -    (189,505)   -    -    -    -    (189,505)
Fair value of warrants issued in private placements   -    (1,279,215)   -    -    -    -    (1,279,215)
Share-based payments   -    -    -    -    320,689    -    320,689 
Loss for the period   -    -    -    -    -    (4,409,782)   (4,409,782)
Balance - February 28, 2013   51,411,961   $8,058,173   $-   $1,493,637   $1,979,280   $(14,727,295)  $(3,196,205)
                                    
Balance - August 31, 2013   57,946,160   $13,180,677   $5,155,674   $1,493,637   $2,232,526   $(25,204,026)  $(3,141,512)
                                    
Proceeds of private placements   11,428,570    12,000,000    (5,000,000)   -    -    -    7,000,000 
Issuance costs of private placements   -    (907,801)   -    -    386,898    -    (520,903)
Issuance of performance shares   1,515,152    422,728    -    (422,728)   -    -    - 
Proceeds from exercise of warrants   5,790,700    3,812,649    (155,674)   -    -    -    3,656,975 
Transfer to share capital on exercise of warrants   -    6,517,181    -    -    -    -    6,517,181 
Proceeds from exercise of options   1,379,168    530,356    -    -    -    -    530,356 
Transfer to share capital on exercise of options   -    463,181    -    -    (463,181)   -    - 
Share-based payments   -    -    -    -    706,423    -    706,423 
Loss for the period   -    -    -    -    -    (5,617,839)   (5,617,839)
Balance - February 28, 2014   78,059,750   $36,018,971   $-   $1,070,909   $2,862,666   $(30,821,865)  $9,130,681 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

6
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

1.Nature of Operations and Going Concern

 

Stellar Biotechnologies, Inc. (“the Company”, formerly CAG Capital Inc.) is listed on the TSX Venture Exchange (‘the Exchange”) as a Tier 2 issuer under the trading symbol KLH since April 19, 2010 (formerly under CAG.P) and in the US under the trading symbol SBOTF as of April 4, 2012, and uplisted to OTCQB effective January 14, 2013.

 

On April 7, 2010, the Company changed its name to Stellar Biotechnologies, Inc. On April 12, 2010, the Company completed a reverse merger transaction with Stellar Biotechnologies, Inc. (“Stellar CA”) which is incorporated under the laws of the State of California, USA. The Company’s head office is 332 E. Scott Street, Port Hueneme, California, 93041, USA, and the registered and records office is 1500 Royal Centre, 1055 West Georgia Street, P.O. Box 11117, Vancouver, BC, V6E 4N7, Canada.

 

The Company’s business is to commercially produce and market Keyhole Limpet Hemocyanin (“KLH”) as well as to develop new technology related to culture and production of KLH and subunit KLH (“suKLH”) formulations. The Company markets KLH and suKLH formulations to customers in the United States and Europe.

 

The Company has received grants for the development of new technology from the National Institutes of Health, National Cancer Institute (“NIH”), the National Science Foundation (“NSF”) including grants under its Technology Enhancement for Commercial Partnerships (“TECP”) program, and Internal Revenue Service (“IRS”) qualifying therapeutic discovery project grants.

 

For the six months ended February 28, 2014, the Company reported a loss of $5,617,839 (2013 - $4,409,782), an accumulated deficit of $30,821,865 (August 31, 2013 - $25,204,026) and working capital of $14,227,870 (August 31, 2013 - $4,225,714).

 

In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract income, and commercial sales. Management believes these financial resources are adequate to support the Company’s initiatives at the current level for the foreseeable future. Management is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, and additional equity financing.

 

The accompanying financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

 

The condensed interim consolidated financial statements of the Company are presented in US dollars, unless otherwise stated, which is the functional currency.

 

2.Basis of Presentation

 

International Financial Reporting Standards and Statement of Compliance

 

These condensed interim consolidated financial statements are prepared in accordance with International Accounting Standards (“IAS”) 34 Interim Financial Reporting using International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”), applicable to the preparation of the financial statements.

 

7
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

2.Basis of Presentation (continued)

 

Basis of Presentation

 

The condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value. In addition, these financial statements have been prepared using the accrual basis of accounting except for cash flow information.

 

The preparation of these condensed interim consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the application of policies and reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the period. Actual results could differ from these estimates.

 

These condensed interim consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the condensed interim consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

 

3.Significant Accounting Policies

 

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited annual consolidated financial statements as at August 31, 2013. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended August 31, 2013.

 

New accounting standards, amendments and interpretations

 

A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2013. The Company has adopted the following standards effective September 1, 2013 and they do not have significant effect on the condensed interim consolidated financial statements:

 

·IFRS 10 - Consolidated Financial Statements. IFRS 10 establishes principles for the presentation and preparation of consolidated financial statements when an entity controls one or more other entities. This standard supersedes IAS 27 Consolidated and Separate Financial Statements and SIC-12 Consolidated – Special Purpose Entities. The adoption of IFRS 10 did not result in any change in the Company’s scope of consolidation or the Company’s financial statements.

 

·IFRS 11 - Joint Arrangements. IFRS 11 establishes principles for financial reporting by parties to a joint arrangement. This standard supersedes IAS 31 Interest in Joint Ventures and SIC-13 Jointly Controlled Entities – Non-Monetary Contributions by Venturers. The adoption of IFRS 11 did not result in any change in the Company’s financial statements.

 

·IFRS 12 - Disclosure of Interests in Other Entities. IFRS 12 is a comprehensive standard on disclosure requirements for all forms of interests in other entities, including subsidiaries, joint operations, joint ventures, associates and unconsolidated structured entities. This standard replaces the disclosure requirements of IAS27 Consolidated and Separate Financial Statements, IAS 28 Investments in Associates, and IAS 31 Interests in Joint Ventures. The adoption of IFRS 12 did not result in any change in the Company’s financial statements.

 

8
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

3.Significant Accounting Policies (continued)

 

·IFRS 13 - Fair Value Measurement.  IFRS 13 is a new standard that applies to both financial and non-financial items measured at fair value.  It defines fair value, sets out a single framework for measuring fair value and requires disclosures about fair value measurements.  The standard applies prospectively from the beginning of the annual period in which it is adopted. The adoption of IFRS 13 did not require adjustments to the Company’s fair value measurement methods, which remain unchanged. The adoption of IFRS 13 did not result in any change in the Company’s financial statements.

 

Accounting standards issued but not yet applied

 

A number of new standards, amendments to standards and interpretations have been issued but are not yet effective until future years. The Company does not expect to adopt any of these standards before their effective dates. The extent of the effects of these new accounting standards on the condensed interim consolidated financial statements has not been determined. The following new standards have not been applied in preparing these condensed interim consolidated financial statements:

 

·IFRS 9 - Financial Instruments. This standard partially replaces IAS 39 - Financial Instruments: Recognition and Measurement. IFRS 9 establishes principles for the classification and measurement of financial assets. The standard is effective for annual periods beginning on or after January 1, 2015.

 

4.Amounts Receivable

 

   February 28,   August 31, 
   2014   2013 
         
Amounts receivable  $15,025   $12,623 
Contracts receivable   50,600    5,025 
Grants receivable   -    157,297 
GST or HST receivable   3,854    2,775 
           
   $69,479   $177,720 

 

9
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

5.Property, Plant and Equipment

 

           Computer                 
   Aquaculture       and Office   Tools and       Leasehold   Total 
Cost:  System   Laboratory   Equipment   Equipment   Vehicles   Improvements   PP&E 
                                    
Balance - August 31, 2013  $58,923   $62,033   $56,710   $393,497   $10,997   $59,107   $641,267 
                                    
Additions   -    -    18,116    226,572    -    -    244,688 
                                    
Balance - February 28, 2014  $58,923   $62,033   $74,826   $620,069   $10,997   $59,107   $885,955 

 

           Computer                 
   Aquaculture       and Office   Tools and       Leasehold   Total 
Accumulated depreciation:  System   Laboratory   Equipment   Equipment   Vehicles   Improvements   PP&E 
                                    
Balance - August 31, 2013  $(47,836)  $(62,033)  $(26,604)  $(213,243)  $(5,499)  $(39,783)  $(394,998)
                                    
Additions   (1,517)   -    (6,874)   (52,712)   (1,100)   (2,569)   (64,772)
                                    
Balance - February 28, 2014  $(49,353)  $(62,033)  $(33,478)  $(265,955)  $(6,599)  $(42,352)  $(459,770)

 

           Computer                 
   Aquaculture       and Office   Tools and       Leasehold   Total 
Carrying Value:  System   Laboratory   Equipment   Equipment   Vehicles   Improvements   PP&E 
                                    
Balance - August 31, 2013  $11,087   $-   $30,106   $180,254   $5,498   $19,324   $246,269 
                                    
Balance - February 28, 2014  $9,570   $-   $41,348   $354,114   $4,398   $16,755   $426,185 

 

6.Licensing Rights

 

During fiscal 2010, the Company paid a $200,000 license fee for intellectual property arising under a research collaboration agreement to a customer for licensing rights outside the customer’s field of use. The customer and the Company jointly own the rights to practice the resulting intellectual properties within specified fields of use. The research collaboration agreement terminated August 31, 2011 and there are no further milestone payments. The related licensing rights do not have a fixed term or termination provisions. The license rights are amortized over the estimated useful life of seven years and are shown net of accumulated impairment losses, if any.

 

   Licensing   Accumulated   Carrying 
   Rights   Amortization   Amount 
             
Balance - August 31, 2013  $200,000   $(83,333)  $116,667 
                
Amortization expense   -    (14,286)   (14,286)
                
Balance - February 28, 2014  $200,000   $(97,619)  $102,381 

 

10
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

6.Licensing Rights (continued)

 

During the year ended August 31, 2013, the Company entered into a license agreement for exclusive rights to patented technology to develop, manufacture and sell human immunotherapies to treat Clostridium difficile infection (“C. diff”). The agreement provides for license fees of $25,000 during the year ended August 31, 2013, $200,000 in fiscal 2014 and $20,000 annually thereafter, creditable against royalties due, if any. Royalties are payable for a mid-single digit percentage of related net sales, if any. License fees are also payable for a low-double digit percentage of related non-royalty sublicensing revenue, if any. The Company reimbursed patent filing, prosecution and maintenance costs of approximately $12,000 during the six months ended February 28, 2014 (year ended August 31, 2013 - $50,000), and will reimburse future patent costs. The license agreement does not have a fixed term or termination provisions. License fees and patent cost reimbursements since the inception of the agreement, have been accounted for as research expense in accordance with IAS 38 Intangible Assets.

 

After execution of the license agreement during the year ended August 31, 2013, the Company issued 371,200 shares of common stock and 278,400 non-transferable share purchase warrants as described in Note 8.

 

The license agreement provides for milestone payments totaling $63,045,000 upon achievement of various financing, development and sales targets. A milestone payment of $100,000 was made during the six months ended February 28, 2014, however, there can be no assurance that other milestones will be met in the future.

 

7.Commitments

 

The Company leases three buildings and facilities under sublease agreements with the Port Hueneme Surplus Property Authority. On September 1, 2010, the Company exercised its option to extend the three buildings and facilities sublease agreements for five years. The Company has an option to extend the lease for another five years.

 

The Company also leases office facilities effective July 1, 2011 for a term of three years with the option to extend for an additional two years. The Company must also pay a portion of the common area maintenance.

 

Future minimum lease payments are as follows:

 

   February 28,   August 31, 
   2014   2013 
For The Year Ending August 31,          
2014  $66,652   $143,735 
2015   89,796    89,349 
2016   14,966    14,892 
           
   $171,414   $247,976 

 

Rent expense on these lease agreements for the six months ended February 28, 2014 was $90,256 (2013 - $87,972).

 

The Company has purchase order commitments totalling approximately $300,000 as at February 28, 2014, for contracts and consultants (August 31, 2013 - $45,000).

 

The Company has two commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer’s field of use. These agreements automatically renew each January unless terminated in writing by either party.

 

11
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital

 

Authorized: unlimited common shares without par value.

 

Private Placements During the Six Months Ended February 28, 2014:

 

Closed a private placement and issued 11,428,570 units for total gross proceeds of $12,000,000, completed in two closings. The private placement included a brokered portion sold to institutional and accredited investors totaling $5,000,000 (4,761,903 units) (the “Brokered Offering”) and a non-brokered portion totalling $7,000,000 (6,666,667 units) (the “Non-brokered Offering”). The non-brokered offering included a $5,000,000 investment by a privately-held Taiwan biopharmaceuticals manufacturer. Each unit, sold for $1.05, comprises one share of the Company’s common stock and one half of a share purchase warrant (each whole warrant, a “Warrant”). Each warrant entitles the holder to purchase one additional share of the Company’s common stock at a purchase price of $1.35 for a period of three years from the issuance date of the warrants. A broker received $346,325 and 333,333 agent warrants (the “Agent Warrants”) valued at $386,898 using the Black Scholes model. Each agent warrant entitles the holder to purchase one additional share of the Company’s common stock at a purchase price of $1.05 for a period of three years from the issuance date of the agent warrants. A total of 200,000 agent warrants are exercisable at $1.05 on or before September 9, 2016 and 133,333 agent warrants are exercisable at $1.05 on or before September 20, 2016. Subject to additional requirements imposed by the US Securities Act requiring longer hold-periods on certain of the securities for resale by US subscribers in the US market and a lock-up agreement with certain holders of the securities, the securities issued in the Initial Closing (2,857,143 brokered offering units, 6,666,667 non-brokered offering units, and 200,000 agent warrants) were subject to a hold period that expired January 10, 2014 and the securities issued in the Final Closing (1,904,760 brokered offering units and 133,333 agent warrants) were subject to a hold period that expired January 21, 2014. The Company paid $170,578 cash share issuance costs in relation to the private placement.

 

Private Placements During the Year Ended August 31, 2013:

 

a)In October 2012, the Company issued 4,000,000 units at a price of CDN$0.25 per unit for gross proceeds of $1,007,900 (CDN$1,000,000). Each unit comprised one common share of the Company and one transferable share purchase warrant. Each warrant entitles the holder to purchase one common share of the Company at a price of CDN$0.40 exercisable on or before October 25, 2015. The warrants were valued at $830,975. Agent’s options were issued to acquire 400,000 units of the Company (valued at $90,995) under the same terms of the private placement and are exercisable at CDN$0.25 on or before October 25, 2015. The Company paid $50,395 of cash share issuance costs in relation to the private placement.

 

b)In January 2013, the Company issued 1,998,400 units at a price of CDN$0.25 per unit for gross proceeds of $502,098 (CDN$499,600). Each unit comprised one common share of the Company and one transferable share purchase warrant. Each warrant entitles the holder to purchase one common share of the Company at a price of CDN$0.40 exercisable on or before January 4, 2016. The warrants were valued at $448,240. Agent’s options were issued to acquire 97,200 units of the Company (valued at $23,693) under the same terms of the private placement and are exercisable at CDN$0.25 on or before January 4, 2016. The Company paid $24,422 of cash share issuance costs in relation to the private placement.

 

c)In April 2013, the Company issued 3,260,000 units at a price of CDN$0.50 per unit for gross proceeds of $1,605,877 (CDN$1,630,000). Each unit comprised one common share of the Company and one half of a transferable share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of CDN$0.75 exercisable on or before October 2, 2014. The warrants were valued at $469,789. Agent’s options were issued to acquire 102,000 units of the Company (valued at $36,206) under the same terms of the private placement and are exercisable at CDN$0.50 on or before October 2, 2014. The Company paid $50,245 of cash share issuance costs in relation to the private placement.

 

12
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital (continued)

 

Performance Shares

 

There were 10,000,000 performance shares set aside for officers, directors and employees of Stellar based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products.

 

During the year ended August 31, 2011, the Company reached the first performance share milestone and issued 3,333,335 shares of the Company to the individuals named in the Performance Share Plan. Accordingly, $930,000 was transferred from shares to be issued to share capital.

 

During the year ended August 31, 2012, the Company reached the final two share milestones and issued 1,313,130 shares of the Company to non-director individuals named in the Performance Share Plan. Accordingly, $366,363 was transferred from shares to be issued to share capital.

 

During the six months ended February 28, 2014, the Company issued 1,515,152 shares of the Company to a former Director named in the Performance Share Plan. Accordingly, $422,728 was transferred from shares to be issued to share capital. As at February 28, 2014, there are 3,838,383 performance shares outstanding to be issued.

 

No amounts were recorded as share-based payments during the six months ended February 28, 2014 or 2013 since the performance shares had fully vested during the prior years.

 

License Agreement

 

During the year ended August 31, 2013, the Company entered into a license agreement and issued 371,200 shares of the Company and 278,400 non-transferable share purchase warrants. Each warrant entitles the holder to purchase one common share in the share capital of the Company at a price of CDN$1.25 per share on or before January 23, 2015. The value of the shares and warrants has been recorded as research and development expense.

 

13
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital (continued)

 

Warrants

 

A summary of the Company’s outstanding warrants is as follows:

 

   Number of
Warrants
   Weighted
Average
Exercise Price
 
       CDN $ 
Balance - August 31, 2012   8,058,600   $1.01 
           
Granted   8,507,500    0.49 
Exercised   (2,738,000)   0.57 
Expired   (1,905,600)   0.54 
           
Balance - August 31, 2013   11,922,500   $0.58 
           
Granted   6,085,712    1.48 
Exercised   (5,790,700)   0.69 
           
Balance - February 28, 2014   12,217,512   $0.95 

 

The weighted average trading price at the date the warrants were exercised during the six months ended February 28, 2014 was CDN$1.85 (2013 - $Nil). The weighted average contractual life remaining on the outstanding warrants is 1.97 years (August 31, 2013 - 1.24 years).

 

The following table summarizes information about the warrants outstanding as at February 28, 2014:

 

Exercise Price  Number of
Warrants
   Expiry Date   
           
CDN$0.75   1,111,900   October 2, 2014   
CDN$0.50   85,200   October 2, 2014  Agent options
CDN$1.25   278,400   January 23, 2015   
CDN$0.40   4,000,000   October 25, 2015   
CDN$0.25   400,000   October 25, 2015  Agent options
CDN$0.40   278,400   January 4, 2016   
CDN$0.25   66,000   January 4, 2016  Agent options
$1.35   4,711,902   September 9, 2016   
$1.05   200,000   September 9, 2016  Agent warrants
$1.35   952,377   September 20, 2016   
$1.05   133,333   September 20, 2016  Agent warrants
            
    12,217,512       

 

14
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital (continued)

 

Agent options are convertible into units. A unit consists of one common share and may include an additional whole or partial warrant. The agent options expiring October 2, 2014 include one-half warrant. The agent options expiring October 25, 2015 and January 4, 2016 include one warrant. The agent warrants expiring September 9, 2016 and September 20, 2016 are convertible into one common share each and do not include additional warrants.

 

Warrant Liability

 

Equity offerings were completed in previous years whereby warrants were issued with exercise prices denominated in Canadian dollars. The Company’s functional currency is in US dollars. As a result of having exercise prices denominated in other than the Company’s functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the condensed interim consolidated statements of loss and comprehensive loss. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in share capital along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment.

 

The fair value of the warrants is determined using the Black-Scholes option pricing model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity.

 

The fair value of warrants exercised during the six months ended February 28, 2014 and 2013 was determined using the Black-Scholes option pricing model, using the following assumptions:

 

   2014   2013 
Risk free interest rate   1.07%   N/A 
Expected life (years)   0.26    N/A 
Expected share price volatility   106%   N/A 

 

The fair value of warrants granted was determined using the Black-Scholes option pricing model, using the following weighted average assumptions at the end of each reporting period:

 

   2014   2013 
Risk free interest rate   1.48%   1.16%
Expected life (years)   3.0    3.0 
Expected share price volatility   112%   127%
Expected dividend yield   0%   0%

 

Option pricing models require the input of highly subjective assumptions regarding volatility. The Company has used historical volatility to estimate the volatility of the share price.

 

15
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital (continued)

 

Options

 

The Company has a stock option plan (“the Plan”) to be administered by the Board of Directors, which has the discretion to grant options for up to a maximum of 20% of the issued and outstanding share capital amount and subject to a maximum of 10,000,000 shares. The exercise price of an option is subject to a minimum of CDN$0.05 preceding the grant date. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule:

 

(a)One-third shall vest immediately;

 

(b)One-third shall vest 12 months from the Effective Date; and

 

(c)One-third shall vest 18 months from the Effective Date.

 

Stock options granted to investor relations vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the previous vesting.

 

Options have been issued under the Plan allowing the holders to purchase common shares of the Company as follows:

 

   Number of
Options
   Weighted
Average
Exercise Price
 
       CDN $ 
Balance - August 31, 2012   5,789,200   $0.42 
           
Granted   1,200,000    0.43 
Exercised   (164,999)   0.45 
Forfeited   (235,333)   0.49 
           
Balance - August 31, 2013   6,588,868   $0.42 
           
Granted   695,000    2.01 
Exercised   (1,379,168)   0.41 
Forfeited   (1,667)   0.42 
           
Balance - February 28, 2014   5,903,033   $0.60 

 

16
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

8.Share Capital (continued)

 

The weighted average trading price at the date the options were exercised during the six months ended February 28, 2014 was CDN$1.77 (2013 - $Nil). The weighted average contractual life remaining on the outstanding options is 4.60 years (August 31, 2013 - 4.75 years).

 

The following table summarizes information about the options under the Plan outstanding and exercisable as at February 28, 2014:

 

Exercise
Price
  Number of
Options
   Exercisable at
February 28, 2014
   Expiry Date
            
CDN$0.25   187,500    187,500   October 23, 2015
CDN$0.28   1,645,000    1,645,000   April 9, 2017
CDN$0.25   55,000    55,000   May 17, 2017
CDN$0.28   20,000    20,000   June 28, 2017
CDN$0.28   70,000    70,000   July 13, 2017
CDN$0.64   70,000    70,000   October 25, 2017
CDN$1.00   60,000    60,000   February 10, 2018
CDN$0.65   848,600    848,600   August 8, 2018
CDN$0.50   5,000    5,000   September 26, 2018
CDN$1.87   100,000    33,333   November 7, 2018
CDN$0.40   70,000    70,000   December 22, 2018
CDN$0.42   853,600    853,600   April 13, 2019
CDN$0.29   90,000    90,000   June 18, 2019
CDN$0.37   150,000    150,000   August 9, 2019
CDN$0.37   150,000    150,000   August 16, 2019
CDN$0.25   58,333    33,333   October 23, 2019
CDN$0.25   215,000    143,334   December 19, 2019
CDN$0.58   560,000    186,667   May 14, 2020
CDN$0.58   100,000    33,333   May 23, 2020
$1.83   495,000    165,000   November 1, 2020
$1.84   100,000    33,333   November 15, 2020
              
    5,903,033    4,903,033    

 

Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s stock options. The estimated fair value of the stock options granted during the six months ended February 28, 2014 and 2013 was determined using a Black-Scholes option pricing model with the following weighted average assumptions:

 

   2014   2012 
Risk free interest rate   1.98%   1.42%
Expected life (years)   6.42    5.0 
Expected share price volatility   120%   124%
Expected dividend yield   0%   0%

 

The average fair value of stock options awarded during the six months ended February 28, 2014 was $1.43 or CDN$1.49 (2013 - CDN$0.25).

17
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

9.Collaboration Agreement

 

In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwan biopharmaceuticals manufacturer to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy using Stellar’s GMP grade Keyhole Limpet Hemocyanin (“KLH”). Under the terms of the agreement, the Company will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in OBI-822 immunotherapy and will also be responsible for method development, product formulation, and process qualification for certain KLH reference standards. The partner will be responsible for development objectives and product specifications. The agreement provides for the partner to pay fees for certain expenses and costs associated with the development program.

 

10.Related Party Disclosures

 

The Company had the following transactions with key management personnel including directors and officers of the Company and their family members. There are no other related parties as defined by IAS 24.

 

   February 28,   February 28, 
   2014   2013 
         
Salaries  $627,824   $273,550 
Short-term employee benefits   23,900    33,194 
Director fees   13,750    4,000 
Consulting fees   -    13,200 
Professional fees   8,658    27,229 
Share-based payments   488,521    232,822 
   $1,162,653   $583,995 

 

Share-based payments are the fair value of the options granted plus the vested value of performance shares.

 

As at February 28, 2014, $4,000 (August 31, 2013 - $2,800) of these amounts remained unpaid and are included in accounts payable and accrued liabilities on the condensed interim consolidated statements of financial position.

 

On August 14, 2002, the Company entered into an agreement to pay royalties to a director and officer in exchange for assignment of patent rights to the Company. The royalty is 5% of gross receipts in excess of $500,000 annually from products using this invention. The Company’s current operations utilize this invention. The royalties for the six months ended February 28, 2014 were $Nil (2013 - $Nil).

 

18
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

11.Supplemental Disclosure of Cash Flow and Non-Cash Transactions

 

Supplemental disclosure of cash paid for taxes and interest and non-cash financing and investing activities include the following:

 

   February 28,   February 28, 
   2014   2013 
         
Financing activities:          
Share issuance costs - agent's options and warrants  $386,898   $114,688 
Warrant valuations on private placements   -    1,279,215 
Transfer to share capital on exercise of warrants   6,517,181    - 
Transfer to share capital on exercise of options   463,181    - 
Transfer to share capital on issuance of performance shares   422,728    - 
Shares subscribed transferred to share capital   5,155,674    - 
           
Cash paid during the period for taxes   12,200    800 
Cash paid during the period for interest   -    - 

 

12.Financial Instruments and Risk Management

 

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity risk, credit risk, foreign exchange risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

 

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity risk, credit risk, foreign exchange risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

 

Capital Management

 

The Company manages its capital to safeguard the Company’s ability to continue as a going concern, so that it can continue to provide adequate returns to shareholders and benefits to other stakeholders, and to have sufficient funds on hand for business opportunities as they arise.

 

The Company considers the items included in share capital as capital. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through short-term prospectuses, private placements, sell assets, incur debt, or return capital to shareholders. As at February 28, 2014, the Company does not have any debt and is not subject to externally imposed capital requirements.

 

Interest Rate Risk

 

Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate as a result in market interest rates. The Company is exposed to interest rate risk to the extent that the cash maintained at the financial institutions included in the Company’s cash and cash equivalents are subject to a floating rate of interest.

 

19
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

12.Financial Instruments and Risk Management (continued)

 

The interest rate risks on cash are not considered significant.

 

Foreign Exchange Risk

 

The Company incurs operating expenses and capital expenditures mostly in US dollars, with some operating expenses incurred in Canadian dollars which are subject to foreign currency fluctuations. The fluctuation of the US dollar in relation to Canadian dollars will have an impact upon the profitability of the Company and may also affect the value of the Company’s assets and the amount of shareholders’ equity. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. As at February 28, 2014, the Company had approximately $5,928,000 Canadian dollars and the US dollar was equal to 1.114 Canadian dollars. Based on the exposure as at February 28, 2014, a 5% change in the Canadian/US exchange rate would impact the Company’s loss and comprehensive loss by approximately $296,000.

 

Credit Risk

 

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and amounts receivable. Management’s assessment of the Company’s credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations.

 

Approximately 76% of the Company’s commercial sales and contract income during the six months ended February 28, 2014 were from two customers (2013 - 97% from three customers). All of the grant revenue during the six months ended February 28, 2014 was received from NSF (2013 - 100% from NSF).

 

Approximately 78% of the Company’s amounts receivables at February 28, 2014, were from two customers (August 31, 2013 - 10% from six customers), Nil% from NSF grants (August 31, 2013 - 88%) and 5% from GST/HST refund (August 31, 2013 - 6%).

 

While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for amounts receivable at the amount recorded on the statement of financial position.

 

Liquidity Risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company attempts to manage liquidity risk by maintaining sufficient cash and cash equivalent balances. Liquidity requirements are managed based on expected cash flows to ensure that there is sufficient capital in order to meet short term obligations. As at February 28, 2014, the Company had a cash and cash equivalents balance of $15,840,974 (August 31, 2013 - $7,859,889) to settle current liabilities of $520,140 exclusive of $1,242,443 noncash current portion of warrant liability (August 31, 2013 - $454,063 exclusive of $3,454,745 noncash current portion of warrant liability).

 

Fair Value

 

The fair value of the Company’s financial instruments is believed to equal the carrying amounts due to the short terms to maturity.

 

20
 

 

Stellar Biotechnologies, Inc.
Notes to Condensed Interim Consolidated Financial Statements
For the Six Months Ended February 28, 2014
(Expressed in US Dollars)

 

12.Financial Instruments and Risk Management (continued)

 

Fair value measurement disclosures include classification of financial instrument fair values in a fair value hierarchy comprising three levels reflecting the significance of the inputs used in making the measurements, described as follows:

 

Level 1:Valuations based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2:Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices such as quoted interest or currency exchange rates; and
Level 3:Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

 

The Company’s fair value of cash and cash equivalents under the fair value hierarchy is measured using Level 1 inputs and fair value of the warrant liability is measured using Level 2 inputs.

 

13.Segment Information

 

The Company operates in one reportable segment, the aquaculture, research and development, production and marketing of KLH products. The Company’s operations are in California, USA, and its corporate assets, comprising mainly cash, are located in Canada.

 

   KLH Operations
(USA)
   Corporate
(Canada)
   Total 
   February 28, 2014 
Total assets  $11,203,886   $5,331,033   $16,534,919 
Current liabilities   500,634    1,261,949    1,762,583 
Warrant liability   -    5,641,655    5,641,655 
Revenues from external parties   150,267    -    150,267 
Net loss   (2,130,752)   (3,487,087)   (5,617,839)

 

   February 28, 2013 
Total assets  $653,162   $748,069   $1,401,231 
Current liabilities   426,836    17,939    444,775 
Warrant liability   -    4,152,661    4,152,661 
Revenues from external parties   177,208    -    177,208 
Net loss   (1,225,972)   (3,183,810)   (4,409,782)

 

14.Events After the Reporting Period

 

Subsequent to February 28, 2014, the Company:

 

a)Issued 1,500 common shares upon the exercise of warrants for gross proceeds of CDN$1,125 and issued 62,500 common shares upon the exercise of stock options for gross proceeds of CDN$15,625.

 

21